ArticleJournal of thoracic disease2019

KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49.

Daniel MorgenszternPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.